Avidity Partners Management’s Sarepta Therapeutics SRPT Stock Holding History

Avidity Partners Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-450,000	Closed	-$54.5M	–	87
2023 Q3	$54.5M	Buy	450,000 +152,500	+51%	+$17.2M	2.2%	11
2023 Q2	$34.1M	Sell	297,500 -118,500	-28%	-$15.3M	1.19%	37
2023 Q1	$57.3M	Sell	416,000 -639,000	-61%	-$82.9M	1.9%	20
2022 Q4	$137M	Buy	1,055,000 +106,800	+11%	+$12.4M	2.96%	11
2022 Q3	$105M	Buy	+948,200	New	+$95.6M	2.13%	14
2021 Q1	–	Sell	-217,400	Closed	-$37.1M	–	122
2020 Q4	$37.1M	Buy	+217,400	New	+$32.2M	1.2%	29
2020 Q2	–	Sell	-80,000	Closed	-$7.83M	–	76
2020 Q1	$7.83M	Buy	+80,000	New	+$9.14M	1.08%	33

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Avidity Partners Management's SRPT Position: Q4 2023 in Review

Avidity Partners Management sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 450,000 shares — an estimated $54.5M sold.

Avidity Partners Management first reported a position in SRPT in Q1 2020 and held it in 7 quarters. The position peaked at $137M in Q4 2022. 395 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

Avidity Partners Management reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
Avidity Partners Management sold 450,000 Sarepta Therapeutics shares in Q4 2023, an estimated $54.5M.
Avidity Partners Management first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 7 quarters.
Avidity Partners Management's Sarepta Therapeutics position peaked at $137M in Q4 2022.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Avidity Partners Management's 13F filing for Q4 2023, filed 14 Feb 2024.